¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"heat-shock response element"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inert response
    ºÒȰ¼º¹ÝÀÀ
  • inflammatory response
    ¿°Áõ¹ÝÀÀ
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£, Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£
  • late asthmatic response
    ¸¸±âõ½Ä¹ÝÀÀ, Èıâõ½Ä¹ÝÀÀ
  • lytic response
    ¿ëÇØ¹ÝÀÀ
  • middle latency response
    Áß°£Àẹ¹ÝÀÀ
  • myotatic response
    ±ÙÀ°½ÅÀü¹ÝÀÀ
  • memory immune response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ
  • placebo response
    ¼ÓÀÓ¾à¹ÝÀÀ, Çö󼼺¸¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • pyramidal tract response
    ÇǶó¹Ìµå·Î¹ÝÀÀ, Ãßü·Î¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ
  • response
    ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • frenquency response curve
    Á֯ļö¹ÝÀÀ°î¼±
  • response curve
    ¹ÝÀÀ°î¼±
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • delayed response
    Áö¿¬¹ÝÀÀ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • emotional response
    °¨Á¤¹ÝÀÀ
  • evoked response
    À¯¹ß¹ÝÀÀ
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immune response, primary
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunological response
    ¸é¿ªÇÐÀû¹ÝÀÀ
  • inert response
    ºÒȰ¼º ¹ÝÀÀ
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
  • placebo response
    Çö󼼺¸¹ÝÀÀ, À§¾à¹ÝÀÀ, ¼ÓÀÓ¾à¹ÝÀÀ.
  • placebo response
    Çö󼼺¸¹ÝÀÀ, À§<°¡>¾à¹ÝÀÀ.
  • positive placebo response
    Çö󼼺¸Ä¡·á È¿°ú.
  • pressure response
    À½¾Ð¹ÝÀÀ(ëåäâÚãëë).
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • radiation response
    ¹æ»ç¼±¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ(ÔÑê¬Úãëë).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • piezoelectric element
    ¾ÐÀüÀÚ
  • radioactive element
    ¹æ»ç¼º ¿ø¼Ò(Û¯ÞÒàõ êªáÈ).
  • rare earth element
    ÈñÅä·ù¿ø¼Ò(̷̬ËÈËôËÛ).
  • reticular element
    ¼¼¸Á¼ººÐ
  • series elastic element
    Á÷·Äź¼º¿ä¼Ò (¡­é©áÈ).
  • solid element
    °íü ¼ÒÀÚ
  • tagged element
    Ç¥Áö¿ø¼Ò(øöãÛêªáÈ).
  • tissue element
    Á¶Á÷¿ä¼Ò(¡­é©áÈ).
  • trace element
    ¹Ì·®¿ø¼Ò(Ú°åÖêªáÈ).
  • trace element
    ÃßÀûÀÚ(õÚîæíº)
  • tracer element
    Ç¥Áö¿ø¼Ò(øöãÛêªáÈ).
  • transition element
    ÀüÀÌ¿ø¼Ò(ï®ì¹êªáÈ).
  • transposable element
    ÀüÀ§À¯Àü´ÜÀ§
  • transuranic element
    ÃÊ¿ì¶ó´½¿ø¼Ò(õ±¡­ êªáÈ).
  • tubular element
    ¼¼°ü¼ººÐ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • pleiotypic response
    ´Ù¸é ´ëÀÀ(ÒýØüÓßëë)
  • primary immune response
    ÀÏÂ÷ ¸é¿ª´ëÀÀ(ìéó­Øóæ¹Óßëë)
  • primary response
    ÀÏÂ÷ ´ëÀÀ(ìéó­Óßëë)
  • SOS response
    SOS ´ëÀÀ(Óßëë)
  • staircase response
    °è´Ü ´ëÀÀ(Í­Ó«Óßëë)
  • stringent response
    ¾ö°Ý ´ëÀÀ(åñÌ«Óßëë)
  • tertiary response
    »ïÂ÷´ëÀÀ (ß²ó­Óßëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IR drop of voltage across a resistor produced by a current; ileal resection; immune response; immunizat...
MLR mean length response; middle latency response; mixed lymphocyte reaction
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
SER sebum excretion rate; sensitizer enhancement ratio; sensory evoked response; service; smooth endopla...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ISRE IFN)-stimulated response element
ISRE Interferon Stimulated Response Element
MRE metal response element
PPRE Peroxisome Proliferator Response Element
PRE Polycomb Response Element
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • immune response
    ¸é¿ª ¹ÝÀÀ
  • immunologic response
    ¸é¿ª ¹ÝÀÀ
    Ç׿ø¿¡ ³ëÃâµÊÀ¸·Î½á °³Ã¼ÀÇ ¹ÝÀÀ¼ºÀÌ Æ¯ÀÌÀûÀ¸·Î º¯È­ÇÑ »óÅÂ.
  • learned response
    ÇнÀ ¹ÝÀÀ
    ÇнÀÀ» ½ÃŰ´Â ÀÚ°¡ ÀǵµÇÑ ´ë·Î Çൿ. ¿¹¸¦ µé¸é Á¾ÀÌ ¿ï·Áµµ °³°¡ ħÀ» È긮´Â °ÍÀÌ ÀÖ´Ù.
  • localized protective response
    ±¹¼ÒÀû º¸È£ ¹ÝÀÀ
  • memory immune response
    ¸é¿ªÇÐÀû ±â¾ï ¹ÝÀÀ
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • placebo response
    Çö󼼺¸ ¹ÝÀÀ, °¡¾à ¹ÝÀÀ
  • psychophysiologic response
    ½É¸® »ý¸®Àû ¹ÝÀÀ
  • response
    ¹ÝÀÀ, ÀÀ´ä
    Àڱؿ¡ ÀÇÇÏ¿© ÀϾ´Â ÀÛ¿ëÀ̳ª ¿òÁ÷ÀÓ.
  • response to illness
    Áúº´¿¡ ´ëÇÑ ¹ÝÀÀ
  • sensitization response
    °¨ÀÛ ¹ÝÀÀ
  • stimulus response assessment
    ÀÚ±Ø ¹ÝÀÀ Æò°¡
  • thermal camera time response
    ¿­ Ä«¸Þ¶ó ½Ã°£ ¹ÝÀÀ
  • unconditioned response
    ¹«Á¶°Ç ¹ÝÀÀ
  • wide dynamic range response characteristics
    ±¤µ¿¹üÀ§ ¹ÝÀÀ Ư¡, ±¤µ¿Àû ¹üÀ§ ¹ÝÀÀ Ư¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
biphasic response Two separate and distinct responses that are separated in time, immediate reaction to an antigenic challenge followed by a recurrence of symptoms after an interval of quiescence.
(05 Mar 2000)
booster response The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen.
(18 Nov 1997)
brainstem evoked response audiometry An electrophysiologic measure of auditory function utilizing responses produced by the auditory nerve and the brainstem to repetitive acoustic stimuli.
(05 Mar 2000)
galvanic skin response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
recruiting response <neurology> The gradual increase to a maximum in a reflex when a stimulus of unaltered intensity is prolonged.
(12 Dec 1998)
partial response <oncology> A decrease of at least 50 percent in the sum of the measurements of all evaluable target lesions or tumours seen in a study.
(16 Dec 1997)
relaxation response An integrated hypothalamic reaction resulting in decreased sympathetic nervous system activity which, physiologically and psychologically, is almost a mirror image of the body's response's to Cannon's emergency theory (flight or fight response); can be self-induced through the use of techniques associated with transcendental meditation, yoga, and biofeedback.
See: emergency theory.
(05 Mar 2000)
response An action or movement due to the application of a stimulus.
Origin: L. Respondere = to answer, reply
(18 Nov 1997)
response generalisation <biology> The principle that after an organism learns to respond in a particular manner to a stimulus, that stimulus is effective in eliciting similar responses.
(12 Dec 1998)
response hierarchy Alternative reactions or modes of adjustment to a given situation arranged in the probable order of prior effectiveness; e.g., a mother attempting to discipline an unruly child may first request, cajole, then plead, scold, and finally punish; her behaviours can be ordered along a response hierarchy for further monitoring of effectiveness.
(05 Mar 2000)
response rate <oncology> The percentage of patients showing partial or complete response to the given treatment.
(16 Dec 1997)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
complete response <oncology> The disappearance of all clinical evidence of disease. Unfortunately, this does not necessarily mean cure, as microscopic metastases may remain undetected, are likely to regrow and become resistant to treatment.
May also be used in relation to a pathological specimen, where no residual abnormality can be detected in the specimen, in which cas it is referred to as a pathological complete reponse.
Acronym: CR
(16 Mar 1998)
concentration-response curve <pharmacology> This is a graph produced to show the relation between the exposure concentration of a drug (or other chemical) and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(05 Jan 1998)
conditioned response A response already in an individual's repertoire but which, through repeated pairings with its natural stimulus, has been acquired or conditioned anew to a previously neutral or conditioned stimulus.
See: conditioning.
Compare: unconditioned response.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á